Developing grasshopper neurons show variable levels of guanylyl cyclase activity on arrival at their targets.
The ability of certain grasshopper neurons to respond to exogenously applied donors of nitric oxide (NO) by producing cyclic GMP (cGMP) depends on their developmental state. ODQ, a selective blocker of NO-sensitive guanylyl cyclase, blocks cGMP production at 10(-5) M, thus confirming the nature of the response. Experiments in which the distal axon is separated from its proximal stump before application of an NO donor show that guanylyl cyclase is distributed uniformly throughout the neuron. In the locust abdomen, where segments are formed sequentially, the pattern of guanylyl cyclase up-regulation is predictable and sequential from anterior to posterior. There are two patterns of innervation by cGMP-expressing motor neurons. In the first, typified by muscle 187, an innervating neuron begins to be NO responsive on arrival at its muscle and continues to be so over most of the remainder of embryonic development, including the formation of motor end plates. In the second, typified by a neuron innervating muscle 191, the neuron extends well along the muscle, apparently laying down a number of sites of contact with it, before it becomes NO responsive. In both patterns, however, NO responsiveness marks the neuron's transition from growth cone elongation to the production of lateral branches. Individual muscles receive innervation from multiple motor neurons, some of which express transient NO sensitivity during development and others which do not. With the exception of the leg motor neuron SETi, the first motor neuron to reach any muscle is usually not NO responsive. We suggest that cGMP plays a role in, or reflects, the early stages of communication between a target and specific innervating neurons.
Ball
E E
EE
Molecular Evolution and Systematics Group, Research School of Biological Sciences, Australian National University, Canberra, ACT. ball@rsbs.anu.edu.au
Truman
J W
JW
D000818:Animals; D006152:Cyclic GMP / Q000096:biosynthesis; D004305:Dose-Response Relationship, Drug; D004625:Embryo, Nonmammalian / Q000378:metabolism; D006110:Grasshoppers / Q000033:anatomy & histology* / Q000196:embryology / Q000378:metabolism; D006162:Guanylate Cyclase / Q000378:metabolism*; D007395:Interneurons / Q000378:metabolism; D009046:Motor Neurons / Q000378:metabolism; D009474:Neurons / Q000378:metabolism*; D009475:Neurons, Afferent / Q000378:metabolism; D009569:Nitric Oxide / Q000502:physiology; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology
D010726:Phosphodiesterase Inhibitors; D009569:Nitric Oxide; D006162:Guanylate Cyclase; D006152:Cyclic GMP